Pharmacoeconomic review report : indication : type 2 diabetes mellitus. Ertugliflozin (Steglatro) (Merck Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Type 2 diabetes.

Physical Description:

1 online resource (14 pages)

Edition:

Final.

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2019.

Summary:

Ertugliflozin is an oral antidiabetic drug belonging to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) for whom metformin is inappropriate due to contraindications or intolerance; and adjunct to diet and exercise to improve glycemic control in adult patients with T2DM inadequately controlled on metformin alone or metformin and sitagliptin. The manufacturer is seeking reimbursement as monotherapy for patients with T2DM who have inadequate glycemic control and for whom metformin or a sulfonylurea is inappropriate due to contraindications or intolerances, and as an add-on therapy to metformin in patients who have inadequate glycemic control and have a contraindication or intolerance to sulfonylurea. The recommended starting dose of ertugliflozin is 5 mg, taken once daily in the morning with or without food. The daily dose may be increased to a maximum of 15 mg if additional glycemic control is needed. The manufacturer submitted ertugliflozin at a price of .45 per tablet for both 5 mg and 15 mg doses, or an annual cost of

Notes:

Description based on publisher supplied metadata and other sources.